In 2023, the import of Cortisone, Hydrocortisone, Prednisone, and Prednisolone to the US stood at a significant volume, serving as the baseline for the forecasted data from 2024 onwards. From 2024 to 2028, the import volume shows a slight downward trend, with negligible year-on-year variations indicating a steadiness around 0% to -0.3%. The Compound Annual Growth Rate (CAGR) over this period reflects a subtle decline. Considered over a decade, the volume showcases a consistent decrement, suggesting stability in demand yet hinting at underlying factors such as potential shifts toward domestic production or alternative therapies.

Future trends to watch:

Advancements in biotechnology that may lead to alternative treatments impacting import volumes.
Policy changes influencing pharmaceutical trade and import regulations.
Shifts in healthcare demand due to demographic changes impacting steroid usage or prescription habits.